AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05894538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use.
Study NCT05894538 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
Study NCT05126264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: morning and afternoon
Study NCT05126264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: morning, afternoon and night
Study NCT05979636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novamin containing toothpaste
Description: children's teeth will be brushed using Novamin containing toothpaste.
Study NCT05979636 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride containing toothpaste
Description: children's teeth will be brushed using Fluoride containing toothpaste.
Study NCT04829474 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: It is a survey that the patient and doctor must complete.
Study NCT04194736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound scan
Description: First ultrasound scan from 1 day to 6 days after the placement of the percutaneous central venous catheter.~Second ultrasound scan from 7 days to 13 days after the placement of the percutaneous central venous catheter if no thrombosis was detected at the first ultrasound scan.
Study NCT04720274 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electromyopathy (EMG) Shorts
Description: Participants will be asked to complete physical activities while wearing EMG shorts
Study NCT04720274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyopathy (EMG) Shorts
Description: Participants will be asked to complete physical activities while wearing EMG shorts
Study NCT06511219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: maxillary segmental distalization
Description: maxillary segmental distalization using skeletal anchored digitally printed appliances
Study NCT05838885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhGH
Description: YPEG-rhGH, 140μg/kg, s.c., once a week, for 52 weeks
Study NCT05838885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhGH
Description: YPEG-rhGH, 280μg/kg, s.c., once a week, for 52 weeks
Study NCT05838885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGH
Description: rhGH, 245μg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks
Study NCT05838885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhGH
Description: rhGH, 470μg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks
Study NCT05319145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: 1) Multi-component exercise intervention program based on Vivifrail©. It consists of 1 daily-30 minutes session, twice a week, for 10 consecutive weeks supervised by an experienced exercise specialist. Exercises (resistance, gait retraining, balance training) are personalized depending on the person's functional capacity (evaluated by the SPPB and a walking speed test) and the risk of falling. Between sessions, individual, unsupervised training by the own patient, supported in the case by the caregiver, will be stimulated, through the recommendations of ViviFrail©. 2) Nutrition. Personalized recommendations according to nutritional and medical status (active oncologic treatment, remission, or palliative stage) will be offered according to the ESPEN recommendations for cancer patients, aimed at compensating for inadequate energy intake, improving patients' malnutrition risk stage (assessed by means of the MNA-SF).
Study NCT05319145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: General recommendations (written and videos) will be offered.
Study NCT06574789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dosing of IV ganciclovir
Description: IV ganciclovir at standard dosing
Study NCT06574789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Personalised dosing of IV ganciclovir
Description: IV ganciclovir at a personalised dosing calculated using a ganciclovir dosing web app
Study NCT06577337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M5542
Description: Participants will receive single ascending dose of M5542 subcutaneously on Day 1 in Part A. Participants will receive loading dose of M5542 followed by maintenance doses in Part B.
Study NCT06577337 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to M5542 in Part A and Part B.
Study NCT05982392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol 100mg will be given 60 minutes before start of procedure.
Study NCT05982392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium
Description: Naproxen sodium 550mg will be given 60 minutes before start of procedure.
Study NCT05982392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given 60 minutes before start of procedure.
Study NCT04406727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421
Description: UB-421 in combination with their ARV
Study NCT04406727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral (ARV)
Description: Antiretroviral (ARV)
Study NCT04406727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiretroviral (ARV)
Description: Antiretroviral (ARV)
Study NCT04761289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Exercise and Functional Rehabilitation Program
Description: 1. Prescription of multimodal physical exercise.~2. Reeducation of Activities of Daily Living (ADL).~3. Prescription of support products and adaptations of the environment.
Study NCT04761289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Exercise and Functional Rehabilitation Program
Description: 1. Prescription of multimodal physical exercise.~2. Reeducation of Activities of Daily Living (ADL).~3. Prescription of support products and adaptations of the environment.
Study NCT05124964 — intervention group
Intervention type: OTHER
Intervention: PedsQL 4.0 Scale
Description: The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions. The Scale comprises parallel patient self-report and parent proxy-report formats. The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL. PedsQL 4.0 will be evaluated at baseline, yearly through 3 years post-enrollment.
Study NCT05124964 — intervention group
Intervention type: OTHER
Intervention: Short Form-36
Description: Altogether, 36 questions with standardized response choices were organized into eight scales, including physical functioning (PF), role limitations as a result of physical health problems (RP), body pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations as a result of emotional problems (RE), and general mental health (MH). Additionally, reported health transition (HT) was used to evaluate general health changes during the previous year. The raw scores were converted to a 0-100 scale according to the instructions, and higher scores indicated a better HRQOL. Physical component score (PCS) and mental component score (MCS) were also calculated. SF-36 will be evaluated at baseline, yearly through 3 years post-enrollment.
Study NCT05124964 — intervention group
Intervention type: OTHER
Intervention: Chinese Wechsler Intelligence Scale for Children
Description: The intelligence of the child was tested by the China-Wechsler Intelligence Scale for Children (C-WISC), which was revised by Gong and Cai at Hunan Medical University. The C-WISC consists of 11 individual tests that include six verbal tests \[Information (I), Comprehend (C), Sorting (S), Arithmetic (A), Vocabulary (V), and Digit symbol (D)\] and five performance tests \[Picture Completing (PC), Picture Arrangement (PA), Block Pattern (BP), Object Assembly (OA), and Coding (CD)\]. Based on individual testing, vocabulary scores (V), procedure scores (P), and full scores (F) were obtained. Furthermore, the VIQ, PIQ, and full intelligence quotient (FIQ) were calculated progressively . C-WISC will be evaluated at baseline, yearly through 3 years post-enrollment.
Study NCT05294445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation of atrial fibrillation (AF)
Description: Cryo-AF-ablation of pulmonary vein (pulmonary vein isolation = PVI)
Study NCT04835909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modern board and card games group
Description: Modern board and card games group
Study NCT04835909 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paper and pencil tasks group
Description: Paper and pencil tasks group
Study NCT05450341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS over right frontal target
Description: Low frequency (1 Hz) rTMS over right inferior frontal gyrus
Study NCT05450341 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS over right temporal target
Description: Low frequency (1 Hz) rTMS over right posterior superior temporal gyrus
Study NCT04841902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Life Style Intervention Manual (With Exercise Under Supervision)
Description: Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. The exercise will be supervised will other two components will be home based.
Study NCT04841902 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General Advice
Description: General advice to stay healthy and active
Study NCT04841902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Life Style Intervention Manual (Home Based)
Description: Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. All three components will be home based.
Study NCT05332340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BZ371A
Description: Single dose topical administration of 1.5 mL with a concentration of 5 mg/mL of BZ371A.
Study NCT05138575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin + Potassium Chloride
Description: Empagliflozin is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle.~KCl is an active control.
Study NCT05138575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin + Potassium Nitrate
Description: Empagliflozin + KNO3 is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle, as well as increase skeletal muscle perfusion during exercise.
Study NCT05138575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Potassium Chloride + Placebo for Empagliflozin
Description: Active control.
Study NCT04834427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional therapy + S (+)-Ketamine
Description: In principle, there are no specific restrictions on the dosage, mode of administration, timing, and compatibility of S-ketamine hydrochloride injection, but the recommended dosage is given, which is lower than the dosage specified in the instructions.~Recommended use and dosage of S (+)-Ketamine:~1. Intravenous injection：Bolus intravenous injection before skin incision, the dose is 0.1\~0.25 mg/kg; Bolus intravenous injection (dose 0.1\~0.25 mg/kg) before skin incision + continuous intravenous infusion (dose of 0.1\~0.25 mg/kg/h) during operation; Continuous intravenous infusion after surgery with a dose of 0.02\~0.1 mg/kg/h for 24\~48 h.~2. Intramuscular injection：The dose is 2\~4 mg/kg.
Study NCT04834427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
Study NCT05252000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical debridement
Description: subjects will receive traditional non-surgical mechanical debridement of tooth surfaces with scalers and ultrasonics removing supragingival and subgingival plaque
Study NCT05252000 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical debridement
Description: subjects will receive traditional non-surgical mechanical debridement of tooth surfaces with scalers and ultrasonics removing supragingival and subgingival plaque
Study NCT05252000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adjunctive aPDT
Description: Antimicrobial photodynamic therapy will be done at tooth sites by applying a photosensitizing dye methylene blue (0.1mg/ml) with a disposable syringe from the bottom of pocket in a coronal direction. After 3 minutes in situ, the surrounding gingival tissues will be irradiated at six sites around the tooth using a diode laser with a wavelength of 660nm, providing an energy density of 10 J/site, 100mW power, time equal to 100 seconds. After irradiation, the site will be thoroughly rinsed with saline.
Study NCT05252000 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham aPDT
Description: subjects will receive saline and non-light emitting laser on the tooth
Study NCT06346964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education
Description: Health education prepared for chronic disease self-management aims to improve the health behaviors of older adults.
Study NCT05256342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine 60mg
Description: Eight weeks treatment, one pill daily.~1st week 30mg; weeks 2-7th -- 60 mg daily.
Study NCT05256342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib 60 mg
Description: One pill daily for 8 weeks
Study NCT05256342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazol
Description: 20 mg daily; will be taken with Etoricoxib from the second week of treatment
Study NCT06204861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capacitive and Resistive Electric Transfer Therapy
Description: Participants received a 10-minute intervention in CAP mode followed by a 20-minute intervention in RES mode.
Study NCT06204861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: The training program consists of five exercises: single-limb stance, single-limb stance with ball toss, single-limb stance with kicking, step-down with a single-limb stance, and wobble board. The program is conducted three times a week, and the difficulty level is increased every two weeks. Before and following the training, a physiotherapist will lead a warm-up and stretching session.
Study NCT04745065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect2BWell
Description: Please see the description provided for arm 1.
Study NCT05230966 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Conditioning (RIC)
Description: RIC is a non-invasive method that achieves a state of intermittent hypoxia, and is performed by inflating the cuff of the pressure gauge on the left upper arm to 200 mmHg in 4 episodes of five-minute ischemia and reperfusion alternately for 45 minutes.
Study NCT06204861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training Combined with Capacitive and Resistive Electric Transfer Therapy
Description: Participants received a 10-minute intervention in CAP mode followed by a 20-minute intervention in RES mode. However, the B+CRET group received balance training along with CRET treatment.
Study NCT06021275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microneedling with topical application of regular insulin
Description: Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
Study NCT06021275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microneedling with topical application of saline
Description: Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
Study NCT05305391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: The arising gastrointestinal symptoms and inflammation markers from consumption of milk + lactase capsule / placebo.
Study NCT05467566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Exercise protocol + application of active direct current stimulation for 30 minutes.
Study NCT04806347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC) graft
Description: After undergoing a disease specific conditioning regimen (standard of care), participants will receive peripheral blood stem cell transplant from a haploidentical donor or closely matched unrelated donor, depleted of TCR αβ+ and CD19+ cells using the CliniMACS TCR α/β-biotin and CD19 Systems.
Study NCT04806347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS® System
Description: The CliniMACS Cell Selection System is based on magnetic-activated cell sorting mechanism. The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures.
Study NCT05162131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bentracimab (PB2452) 100 mg or Placebo
Description: Experiment 1-a: 100 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion
Study NCT05162131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bentracimab (PB2452) 300 mg or Placebo
Description: Experiment 1-b: 300 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion
Study NCT05162131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bentracimab (PB2452) 1000 mg or Placebo
Description: Experiment 1-c: 1000 mg Bentracimab (PB2452) or Placebo (no Ticagrelor)~Drug: PB2452 Infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion
Study NCT05162131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bentracimab (PB2452) 1000 mg or Placebo (With Ticagrelor Pre-Treatment)
Description: Experiment 2: 1000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo
Study NCT05162131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bentracimab (PB2452) 3000 mg or Placebo (With Ticagrelor Pre-Treatment)
Description: Experiment 3: 3000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo
Study NCT05162131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bentracimab (PB2452) 9000 mg or Placebo (With Ticagrelor Pre-Treatment)
Description: Experiment 4: 9000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo
Study NCT05162131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bentracimab (PB2452) 18000 mg or Placebo (With Ticagrelor Pre-Treatment)
Description: Experiment 5: 18000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo
Study NCT04936529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-glucan
Description: Group 1 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with \~2 weeks on, \~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14). This schedule includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at months 36 (3 years), 48 (4 years), and 60 (5 years).~Group 2 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with \~2 weeks on, \~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14).~Group 3 participants will be treated as in Group 1.
Study NCT04936529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Group 1 participants will not receive GM-CSF.~Group 2 participants will receive GM-CSF (250 mcg/m2/day) x3 days with vaccinations #1-#3; x7 days with vaccinations #4-#11; and x5 days with vaccinations #12-#14.~Group 3 participants will be treated as in Group 1.